Clinical usefulness of serum EBV DNA levels of BamHI W and LMP1 for nasal NK/T-cell lymphoma

Journal of Medical Virology

Volumn 79, Issue 5, 2007, Pages 562-572

  Ishii, Hideyuki ^a   Ogino, Takeshi ^a   Berger, Christoph ^b   Köchli Schmitz, Nicole ^b   Nagato, Toshihiro ^a   Takahara, Miki ^a   Nadal, David ^b   Harabuchi, Yasuaki ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

BamHI W; Epstein Barr virus; LMP1; Nasal NK T cell lymphoma; Quantitative real time polymerase chain reaction

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; LATENT MEMBRANE PROTEIN 1; METHOTREXATE; MITOXANTRONE; PEPLEOMYCIN; PIRARUBICIN; PREDNISOLONE; PROTEIN BAMHI W; UNCLASSIFIED DRUG; VINCRISTINE; VIRUS DNA; VIRUS PROTEIN;

ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE MARKER; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN CELL; LYMPHOMA CELL; MALE; NATURAL KILLER CELL; NONHUMAN; NOSE CANCER; OVERALL SURVIVAL; PATIENT MONITORING; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; T CELL LYMPHOMA; VIRUS REPLICATION;

ADULT; AGED; ANTIGENS, VIRAL; BIOLOGICAL MARKERS; DEOXYRIBONUCLEASE BAMHI; DNA PRIMERS; DNA, VIRAL; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; NOSE NEOPLASMS; PEPTIDE FRAGMENTS; POLYMERASE CHAIN REACTION; PROGNOSIS; VIRAL MATRIX PROTEINS; VIRAL PROTEINS;

HUMAN HERPESVIRUS 4;

EID: 34147117721     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20853     Document Type: Article

References (32)

1. Au WY, Pang A, Choy C, Chim CS, Kwong YL. 2004. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 104:243-249.
2. Aviles A, Diaz NR, Neri N, Cleto S, Talavera A. 2000. Angiocentric nasal T/natural killer cell lymphoma: A single center study of prognostic factors in 108 patients. Clin Lab Haematol 22:215-220.
3. Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ, Hatfull G, Hudson GS, Satchwell SC, Seguin C. 1984. DNA sequence and expression of the B 95-8 Epstein-Barr virus genome. Nature 310:207-211.
4. Berger C, Day P, Meier G, Zingg W, Bossart W, Nadal D. 2001. Dynamics of Epstein-Barr virus DNA levels in serum during EBV-associated disease. J Med Virol 64:505-512.
5. Brousset P, Knecht H, Rubin B, Drouet E, Chittal S, Meggetto F, Saati TA, Bachmann E, Denoyel G, Sergeant A, et al. 1993. Demonstration of Epstein-Barr virus replication in Reed-Sternberg cells of Hodgkin's disease. Blood 82:872-876.
6. Brousset P, Drouet E, Schlaifer D, Icart J, Payen C, Meggetto F, Marchou B, Massip P, Delsol G. 1994. Epstein-Barr virus (EBV) replicative gene expression in tumor cells of AIDS-related non-Hodgkin's lymphoma in relation to CD4 cell number and antibody titers to EBV. AIDS 8:583-590.
7. Carey M, Kolman J, Katz DA, Gradoville L, Barberis L, Miller G. 1992. Transcriptional synergy by the Epstein-Barr virus transactivator ZEBRA. J Virol 66:4803-4813.
8. Chan KC, Lo YM. 2002. Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma. Semin Cancer Biol 12:489-496.
9. Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF, Mo F, Lai M, Ho S, Huang DP, Johnson PJ. 2002. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 94:1614-1619.
10. Chan KC, Zhang J, Chan AT, Lei KI, Leung SF, Chan LY, Chow KC, Lo YM. 2003. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 63:2028-2032.
11. Chiang AK, Tao Q, Srivastava G, Ho FC. 1996. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. Int J Cancer 68:285-290.
12. Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R, Yau CC, Kwong YL. 2004. Primary nasal natural killer cell lymphoma: Long-term treatment outcome and relationship with the International Prognostic Index. Blood 103:216-221.
13. Countryman J, Jenson H, Seibl R, Wolf H, Miller G. 1987. Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J Virol 61:3672-3679.
14. Dehee A, Asselot C, Piolot T, Jacomet C, Rozenbaum W, Vidaud M, Garbarg-Chenon A, Nicolas JC. 2001. Quantification of Epstein-Barr virus load in peripheral blood of human immunodeficiency virus-infected patients using real-time PCR. J Med Virol 65:543-552.
15. Drouet E, Brousset P, Fares F, Icart J, Verniol C, Meggetto F, Schlaifer D, Desmorat-Coat H, Rigal-Huguet F, Niveleau A, Delsol G. 1999. High Epstein-Barr virus serum load and elevated titers of anti-ZEBRA antibodies in patients with EBV-harboring tumor cells of Hodgkin's disease. J Med Virol 57:383-389.
16. Harabuchi Y, Yamanaka N, Kataura A, Imai S, Kinoshita T, Mizuno F, Osato T. 1990. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 335:128-130.
17. Harabuchi Y, Imai S, Wakashima J, Hirao M, Kataura A, Osato T, Kon S. 1996. Nasal T-cell lymphoma causally associated with Epstein-Barr virus: Clinicopathologic, phenotypic, and genotypic studies. Cancer 77:2137-2149.
18. Harabuchi Y, Tsubota H, Ohguro S, Himi T, Asakura K, Kataura A, Ohuchi A, Hareyama M. 1997. Prognostic factors and treatment outcome in non-Hodgkin's lymphoma of Waldeyer's ring. Acta Oncol (Madr) 36:413-420.
19. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. 2000. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 13:193-207.
20. Kim TM, Park YH, Lee SY, Kim JH, Kim DW, Im SA, Kim TY, Kim CW, Heo DS, Bang YJ, Chang KH, Kim NK. 2005. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood 106:3785-3790.
21. Kimura H, Hoshino Y, Hara S, Nishikawa K, Sako M, Hirayama M, Komada Y, Morishima T. 2002. Viral load in Epstein-Barr virus-associated hemophagocytic syndrome. Microbiol Immunol 46:579-582.
22. Ko YH, Ree HJ, Kim WS, Choi WH, Moon WS, Kim SW. 2000. Clinicopathologic and genotypic study of extranodal nasal-type natural killer/T-cell lymphoma and natural killer precursor lymphoma among Koreans. Cancer 89:2106-2116.
23. Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon HC, Kim HJ, Lee SI, Kim JH, Park J, Oh SJ, Kim K, Jung C, Park K, Kim WS. 2006. Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study. J Clin Oncol 24:612-618.
24. Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM. 2002. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma. Clin Cancer Res 8:29-34.
25. Minarovits J, Hu LF, Imai S, Harabuchi Y, Kataura A, Minarovits Kormuta S, Osato T, Klein G. 1994. Clonality, expression and methylation patterns of the Epstein-Barr virus genomes in lethal midline granulomas classified as peripheral angiocentric T cell lymphomas. J Gen Virol 75:77-84.
26. Nadal D, Blasius M, Niggli FK, Meier G, Berger C. 2002. Epstein-Barr virus (EBV) DNA levels in palatine tonsils and autologous serum from EBV carriers. J Med Virol 67:54-58.
27. Nakamura S, Katoh E, Koshikawa T, Yatabe Y, Nagasaka T, Ishida H, Tokoro Y, Koike K, Kagami Y, Ogura M, Kojima M, Nara Y, Mizoguchi Y, Hara K, Kurita S, Seto M, Suchi T. 1997. Clinicopathologic study of nasal T/NK-cell lymphoma among the Japanese. Pathol Int 47:38-53.
28. Takahara M, Kishibe K, Bandoh N, Nonaka S, Harabuchi Y. 2004. P53, N- and K-Ras, and beta-catenin gene mutations and prognostic factors in nasal NK/T-cell lymphoma from Hokkaido, Japan. Hum Pathol 35:86-95.
29. Xu ZG, Iwatsuki K, Oyama N, Ohtsuka M, Satoh M, Kikuchi S, Akiba H, Kaneko F. 2001. The latency pattern of Epstein-Barr virus infection and viral IL-10 expression in cutaneous natural killer/T-cell lymphomas. Br J Cancer 84:920-925.
30. Yamanaka N, Kataura A, Sambe S, Minase T, Ishii Y. 1985. Midfacial T cell lymphoma: Characterization by monoclonal antibodies. Ann Otol Rhinol Laryngol 94:207-211.
31. Zhang Y, Nagata H, Ikeuchi T, Mukai H, Oyoshi MK, Demachi A, Morio T, Wakiguchi H, Kimura N, Shimizu N, Yamamoto K. 2003. Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions. Br J Haematol 121:805-814.
32. Zhang Y, Ohyashiki JH, Takaku T, Shimizu N, Ohyashiki K. 2006. Transcriptional profiling of Epstein-Barr virus (EBV) genes and host cellular genes in nasal NK/T-cell lymphoma and chronic active EBV infection. Br J Cancer 94:599-608.